Developer docs
API playgroundTry for free, no card

Search company profiles

Pluryal

Full company profile

uuid000nbf3

Namestring
Pluryal
Legal namestring
MD Skin Solutions SARL
Websiteurl
pluryal.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Pluryal (operating through the legal entity MD Skin Solutions SARL) is a Luxembourg-headquartered, family-owned medical aesthetics company founded in 1999. The company designs, develops, and sells two core product lines: Pluryal Mesoline, a range of sterile serums with science-based active ingredients for skin, hair, and body treatments administered via micro-needling rollers, and Pluryal Injectables, comprising hyaluronic acid-based dermal fillers for facial contouring and wrinkle correction alongside hyaluronic acid + polynucleotides-based densifiers for skin repair and collagen stimulation. The portfolio addresses face, hair, body, and intimate aesthetic concerns and is individually inspected before market release under ISO 13485 (medical devices) and ISO 22716 (cosmetics) manufacturing standards. A planned green injectables line is intended to extend the injectable range in response to clean beauty demand.

Short descriptiontext

Pluryal is a Luxembourg-based family-owned medical aesthetics company founded in 1999 that designs and sells hyaluronic acid dermal fillers, polynucleotides-based densifiers, and mesoline serums exclusively to licensed medical professionals in over 70 countries via a global distributor network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLuxembourg, Luxembourg
HQ citystring
Luxembourg
HQ countrystring
Luxembourg
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
aesthetic medicine products, dermal filler injectables, cosmetic skincare serums, medical aesthetic supplies, hyaluronic acid treatments
Product category
Aesthetic Medicine
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Aesthetic Products
TypeOne Time License
Description

Sale of medical aesthetic products including dermal fillers, densifiers, and mesoline sterile serums to licensed healthcare professionals and clinics worldwide.

2Distributor Network
TypeOne Time License
Description

Revenue generated through global distributor network selling Pluryal products to medical aesthetic practitioners in more than 70 countries.

pluryal.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Mesoline
Description

Range of sterile serums formulated with science-based active ingredients for skin, hair, and body treatments.

pluryal.com
+1 more record
Core offering1 text field

No factual source-supported description of the company's core offering is present in the provided input. The input block contains no source-attributable product or service description for Pluryal.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Treatment duration of 15-30 minutes with no recovery period required
+2 more records
Product overview1 text field

Pluryal is a European family-owned medical aesthetic company headquartered in Luxembourg that has been designing, developing, and selling products since 1999. The company operates two main product lines: Pluryal Mesoline (a range of sterile serums with science-based active ingredients for skin, hair, and body, delivered via micro-needling) and Pluryal Injectables (hyaluronic acid-based dermal fillers and polynucleotides-based densifiers for facial contouring, wrinkle correction, and skin repair). Treatments cover face, hair, body, and intimate areas across more than 70 countries. The portfolio also includes green injectables planned for launch to meet clean beauty demand.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Pluryal Affiliates
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Affiliated distributors in various countries worldwide responsible for distributing Pluryal products and responding to local customer requests.

pluryal.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global dermatology and aesthetics major with leading hyaluronic acid filler (Restylane) and biostimulator (Sculptra) portfolios sold through medical professionals — directly competes with Pluryal Fillers and Densifiers across face and skin indications.

TypeBroad incumbent
Description

Owns the Juvéderm hyaluronic acid filler family and Botox, the dominant aesthetics franchise globally — competes head-to-head with Pluryal Injectables across facial contouring and wrinkle correction indications.

TypeBroad incumbent
Description

Markets the Belotero HA filler and Radiesse calcium hydroxylapatite biostimulator, overlapping directly with Pluryal's filler and densifier offerings to plastic surgeons and dermatologists.

TypeDirect peer
Description

Swiss-based aesthetics company selling the Teosyal range of hyaluronic acid fillers and mesotherapy products through a global distributor model to medical practitioners — closely comparable in size, technology, and go-to-market approach to Pluryal.

TypeDirect peer
Description

European aesthetics company with HA filler (MaiLi) and collagen-stimulator (Ellansé) lines distributed globally to aesthetic practitioners — comparable mid-sized competitor in the same biostimulator-plus-filler category as Pluryal.

TypeDirect peer
Description

Austrian family-owned aesthetics firm selling Princess HA fillers and a broad mesotherapy portfolio to physicians in 70+ countries — directly comparable in family-owned structure, distributor-led model, and product breadth to Pluryal.

TypeDirect peer
Description

Division of IBSA Group marketing Profhilo (HA-based skin remodeling) and other injectable aesthetics products to practitioners — directly competes with Pluryal's densifier proposition of HA-based bio-remodeling for skin quality.

8Revance Therapeutics
TypeEmerging player
Description

US aesthetics company with the RHA Collection of resilient HA fillers and the DaxibotulinumtoxinA neuromodulator — competes in the premium injectable segment that Pluryal targets, though focused on the US market.

TypeEmerging player
Description

Canadian developer of the Revanesse line of HA dermal fillers distributed internationally to medical aesthetic clinics — comparable mid-sized competitor with a focused injectable portfolio.

TypeEmerging player
Description

German manufacturer of HYACorp HA body and facial fillers distributed to aesthetic practitioners across Europe — comparable European private competitor with a similar HA-filler-led portfolio targeting the same professional channel.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pluryal

Aesthetic Medicinepluryal.com

Pluryal is a Luxembourg-based family-owned medical aesthetics company founded in 1999 that designs and sells hyaluronic acid dermal fillers, polynucleotides-based densifiers, and mesoline serums exclusively to licensed medical professionals in over 70 countries via a global distributor network.

What Pluryal does

Pluryal (operating through the legal entity MD Skin Solutions SARL) is a Luxembourg-headquartered, family-owned medical aesthetics company founded in 1999. The company designs, develops, and sells two core product lines: Pluryal Mesoline, a range of sterile serums with science-based active ingredients for skin, hair, and body treatments administered via micro-needling rollers, and Pluryal Injectables, comprising hyaluronic acid-based dermal fillers for facial contouring and wrinkle correction alongside hyaluronic acid + polynucleotides-based densifiers for skin repair and collagen stimulation. The portfolio addresses face, hair, body, and intimate aesthetic concerns and is individually inspected before market release under ISO 13485 (medical devices) and ISO 22716 (cosmetics) manufacturing standards. A planned green injectables line is intended to extend the injectable range in response to clean beauty demand.

Pluryal firmographics

Firmographics
Name
Pluryal
Legal name
MD Skin Solutions SARL
Website
https://pluryal.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Pluryal is a Luxembourg-based family-owned medical aesthetics company founded in 1999 that designs and sells hyaluronic acid dermal fillers, polynucleotides-based densifiers, and mesoline serums exclusively to licensed medical professionals in over 70 countries via a global distributor network.
Ownership category
akta.pro rank

Where Pluryal is headquartered

Location

Headquarters

HQ city
Luxembourg
HQ country
Luxembourg
HQ region
Europe

Offices1 record

Markets served

Pluryal business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Revenue model

  1. Medical Aesthetic Products: Sale of medical aesthetic products including dermal fillers, densifiers, and mesoline sterile serums to licensed healthcare professionals and clinics worldwide.
  2. Distributor Network: Revenue generated through global distributor network selling Pluryal products to medical aesthetic practitioners in more than 70 countries.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Pluryal product offering

Product offering

Core offering

No factual source-supported description of the company's core offering is present in the provided input. The input block contains no source-attributable product or service description for Pluryal.

Product overview

Pluryal is a European family-owned medical aesthetic company headquartered in Luxembourg that has been designing, developing, and selling products since 1999. The company operates two main product lines: Pluryal Mesoline (a range of sterile serums with science-based active ingredients for skin, hair, and body, delivered via micro-needling) and Pluryal Injectables (hyaluronic acid-based dermal fillers and polynucleotides-based densifiers for facial contouring, wrinkle correction, and skin repair). Treatments cover face, hair, body, and intimate areas across more than 70 countries. The portfolio also includes green injectables planned for launch to meet clean beauty demand.

Differentiator

Problem solved

Functional benefit

Brands

  • Mesoline: Range of sterile serums formulated with science-based active ingredients for skin, hair, and body treatments.
  • Injectables

Quantifiable outcome

  • Treatment duration of 15-30 minutes with no recovery period required
  • +2 more outcomes

Companies that use Pluryal

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles1 record

Pluryal technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pluryal partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Pluryal AffiliatescoreChannel Partner/ Reseller/ DistributorAffiliated distributors in various countries worldwide responsible for distributing Pluryal products and responding to local customer requests.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Pluryal competitors and assessment

Company assessment

Broad incumbents

  • Galderma: Global dermatology and aesthetics major with leading hyaluronic acid filler (Restylane) and biostimulator (Sculptra) portfolios sold through medical professionals — directly competes with Pluryal Fillers and Densifiers across face and skin indications.
  • AbbVie (Allergan Aesthetics): Owns the Juvéderm hyaluronic acid filler family and Botox, the dominant aesthetics franchise globally — competes head-to-head with Pluryal Injectables across facial contouring and wrinkle correction indications.
  • Merz Aesthetics: Markets the Belotero HA filler and Radiesse calcium hydroxylapatite biostimulator, overlapping directly with Pluryal's filler and densifier offerings to plastic surgeons and dermatologists.

Direct peers

  • Teoxane: Swiss-based aesthetics company selling the Teosyal range of hyaluronic acid fillers and mesotherapy products through a global distributor model to medical practitioners — closely comparable in size, technology, and go-to-market approach to Pluryal.
  • Sinclair Pharma: European aesthetics company with HA filler (MaiLi) and collagen-stimulator (Ellansé) lines distributed globally to aesthetic practitioners — comparable mid-sized competitor in the same biostimulator-plus-filler category as Pluryal.
  • Croma-Pharma: Austrian family-owned aesthetics firm selling Princess HA fillers and a broad mesotherapy portfolio to physicians in 70+ countries — directly comparable in family-owned structure, distributor-led model, and product breadth to Pluryal.
  • IBSA Derma: Division of IBSA Group marketing Profhilo (HA-based skin remodeling) and other injectable aesthetics products to practitioners — directly competes with Pluryal's densifier proposition of HA-based bio-remodeling for skin quality.

Emerging players

  • Revance Therapeutics: US aesthetics company with the RHA Collection of resilient HA fillers and the DaxibotulinumtoxinA neuromodulator — competes in the premium injectable segment that Pluryal targets, though focused on the US market.
  • Prollenium Medical Technologies: Canadian developer of the Revanesse line of HA dermal fillers distributed internationally to medical aesthetic clinics — comparable mid-sized competitor with a focused injectable portfolio.
  • BioScience GmbH (HYACorp): German manufacturer of HYACorp HA body and facial fillers distributed to aesthetic practitioners across Europe — comparable European private competitor with a similar HA-filler-led portfolio targeting the same professional channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Pluryal social profiles

Digital presence

Pluryal compliance and trust

Trust signal

Compliance2 records

Pluryal financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pluryal leadership team

Management profile

Number of profiles

Pluryal funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pluryal M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pluryal

What does Pluryal do?

No factual source-supported description of the company's core offering is present in the provided input. The input block contains no source-attributable product or service description for Pluryal.

Is Pluryal a public or private company?

Pluryal is a private company. It is classified as unknown and is currently operating.

When was Pluryal founded?

Pluryal was founded in 1999. It employs 11 to 50 people.

Where is Pluryal based?

Pluryal is headquartered in Luxembourg, Luxembourg, in the Europe region.

How does Pluryal make money?

Two revenue lines are on record. Medical Aesthetic Products are the primary driver. The others are distributor Network.

Who are Pluryal's main competitors?

Broad incumbents on record are Galderma, AbbVie (Allergan Aesthetics) and Merz Aesthetics. Direct peers are Teoxane, Sinclair Pharma, Croma-Pharma and IBSA Derma. Emerging players are Revance Therapeutics, Prollenium Medical Technologies and BioScience GmbH (HYACorp).

Does Pluryal have an API?

No public API is recorded for Pluryal.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales